Fisher Asset Management LLC Trims Position in Sanofi (NASDAQ:SNY)

Fisher Asset Management LLC cut its holdings in shares of Sanofi (NASDAQ:SNY) by 6.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,511,027 shares of the company’s stock after selling 848,083 shares during the quarter. Fisher Asset Management LLC’s holdings in Sanofi were worth $603,407,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. SVB Wealth LLC purchased a new position in Sanofi during the 4th quarter worth approximately $275,000. Altrius Capital Management Inc raised its position in Sanofi by 5.1% during the 4th quarter. Altrius Capital Management Inc now owns 161,940 shares of the company’s stock worth $7,810,000 after buying an additional 7,865 shares during the last quarter. Parkside Financial Bank & Trust raised its position in Sanofi by 12.0% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,250 shares of the company’s stock worth $157,000 after buying an additional 348 shares during the last quarter. Fusion Capital LLC raised its position in Sanofi by 1.6% during the 4th quarter. Fusion Capital LLC now owns 134,687 shares of the company’s stock worth $6,496,000 after buying an additional 2,110 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in Sanofi by 1.0% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 126,811 shares of the company’s stock worth $6,116,000 after buying an additional 1,216 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Price Performance

NASDAQ:SNY opened at $54.47 on Friday. The firm has a market cap of $138.24 billion, a price-to-earnings ratio of 21.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a 50 day moving average price of $51.65 and a 200-day moving average price of $52.61. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.